Anastrozole, an aromatase inhibitor for breast cancer treatment, likely induces alopecia through estrogen depletion, potentially by shortening the anagen phase, increasing shedding (telogen effluvium), or contributing to female pattern hair loss (Karatas et al., 2016). Here, CYP19A1 is linked to breast carcinoma.